Quarterly ResultMay 14, 2026, 04:22 PM
Eton Pharma Q1 Product Sales +73% to $24.3M; Raises 2026 Revenue Guidance
AI Summary
Eton Pharmaceuticals reported strong financial results for the first quarter ended March 31, 2026, with product sales increasing 73% year-over-year to $24.3 million. Based on this performance, the company raised its full-year 2026 revenue guidance to exceed $120 million. Key business achievements include the FDA approval and launch of DESMODA, the acquisition and relaunch of HEMANGEOL, and significant progress in its R&D pipeline with the initiation of the ET-700 clinical study and FDA clearance for the INCRELEX label harmonization study.
Key Highlights
- Q1 2026 product sales grew 73% year-over-year to $24.3 million.
- Raised full-year 2026 revenue guidance to exceed $120 million, up from $110 million.
- Reported Q1 2026 fully diluted GAAP EPS of $0.05 and non-GAAP EPS of $0.14.
- Achieved Q1 2026 Adjusted EBITDA of $5.7 million.
- Received FDA approval for and launched DESMODA, an oral desmopressin solution.
- Acquired U.S. rights to and relaunched HEMANGEOL for $14.0 million.
- Initiated ET-700 clinical study and received FDA clearance for INCRELEX label harmonization study.
- Generated $7.4 million in cash from operations during Q1 2026.